TG THERAPEUTICS, INC.

BRIUMVI

Manufacturer:

TG THERAPEUTICS, INC.

Briumvi HCPCS:

J2329

HCPCS Code Descriptor:

Injection, ublituximab-xiiy, 1mg

Category:

J Code

Briumvi NDCs:

73150-0150-06

Primary Type:

Immunology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Briumvi CPT Codes:

Potential CPT administration codes for Briumvi can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Briumvi:

BRIUMVI is a Immunology drug manufactured by TG THERAPEUTICS, INC. and administered via the Intravenous route of administration. The J Code: J2329 is aligned to the drug BRIUMVI.

ACCESS PRICING AND MORE BY REGISTERING

J2329 Added Date:

July 1, 2023

J2329 Effective Date:

July 1, 2023

J2329 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Briumvi billing and coding information.
Briumvi patient assistance information can be found through Briumvi Patient Support at the URL: https://briumvi.com/briumvi-patient-support/
BRIUMVI prescribing information can be found at the link below:
Information regarding BRIUMVI’s side effects can be found at MedlinePlus